Literature DB >> 15207740

Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures.

K Igarashi1, H Hirotani, J-T Woo, P H Stern.   

Abstract

Studies were carried out to characterize the effects of cyclosporines and FK506 on the formation and survival of osteoclasts deriving from mouse bone marrow cultures. Cyclosporin A (CsA), cyclosporin B (CsB), cyclosporin H (CsH), and FK506 all inhibited receptor activator of NFkappaB ligand (RANKL)-stimulated tartrate-resistant acid phosphatase (TRAP) activity and generation of TRAP+ multinucleated cells in the cultures. CsA and CsG were approximately equipotent, CsH was approximately one order of magnitude less potent than the other cyclosporines, and FK506 was approximately two orders of magnitude more potent than CsA and CsG. All of the inhibitors demonstrated greater potency and efficacy on decreasing the number of TRAP+ multinucleated cells than on decreasing total TRAP activity. Further evidence that late stages were more sensitive to inhibition was obtained in experiments in which CsA was present for different segments of the RANKL-stimulated culture period. CsA was as efficacious when added for the final 2 days of a 4-day culture as when added for the entire culture period, whereas it was less effective if added for only the first 2 days of the culture. When CsA or FK506 were added for 1 day to cultures in which osteoclasts had already formed, the numbers of TRAP+ osteoclasts decreased. Treatment with CsA or FK506 produced nuclear fragmentation and disruption of the multinucleated osteoclasts and an increase in caspase-3 activity. The apoptosis inhibitor z-VAD partially prevented the inhibitory effects of CsA and FK506 on the survival of TRAP+ multinucleated cells in the cultures and also preserved the normal osteoclast morphology. The data indicate that an important component of the inhibitory effects of CsA and FK506 on marrow-derived osteoclasts is the induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207740     DOI: 10.1016/j.bone.2004.02.009

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  FKBP12: A partner of Snx10 required for vesicular trafficking in osteoclasts.

Authors:  Ricardo A Battaglino; Prakash Jha; Farhath Sultana; Weimin Liu; Leslie R Morse
Journal:  J Cell Biochem       Date:  2019-03-19       Impact factor: 4.429

Review 2.  The role of small molecules in musculoskeletal regeneration.

Authors:  Kevin W-H Lo; Keshia M Ashe; Ho Man Kan; Cato T Laurencin
Journal:  Regen Med       Date:  2012-07       Impact factor: 3.806

Review 3.  Roles for NF-kappaB and c-Fos in osteoclasts.

Authors:  Brendan F Boyce; Teruhito Yamashita; Zhenqiang Yao; Qian Zhang; Fang Li; Lianping Xing
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

4.  Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis.

Authors:  Masashi Miyazaki; Yosuke Fujikawa; Chikahiro Takita; Hiroshi Tsumura
Journal:  Clin Rheumatol       Date:  2006-04-04       Impact factor: 2.980

5.  The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms.

Authors:  Sumudra Periyasamy; Manya Warrier; Manoranjani P M Tillekeratne; Weinian Shou; Edwin R Sanchez
Journal:  Endocrinology       Date:  2007-07-05       Impact factor: 4.736

6.  FK506 prevented bone loss in streptozotocin-induced diabetic rats via enhancing osteogenesis and inhibiting adipogenesis.

Authors:  Li-Hua Ni; Ri-Ning Tang; Cheng Yuan; Kai-Yun Song; Li-Ting Wang; Xiao-Chen Wang; Yu-Xia Zhang; Xiao-Liang Zhang; Dong-Dong Zhu; Bi-Cheng Liu
Journal:  Ann Transl Med       Date:  2019-06

7.  Impairment of early fracture healing by skeletal muscle trauma is restored by FK506.

Authors:  Brady J Hurtgen; Beth E P Henderson; Catherine L Ward; Stephen M Goldman; Koyal Garg; Todd O McKinley; Sarah M Greising; Joseph C Wenke; Benjamin T Corona
Journal:  BMC Musculoskelet Disord       Date:  2017-06-12       Impact factor: 2.362

Review 8.  Positive and negative regulators of osteoclast apoptosis.

Authors:  Niroshani Surangika Soysa; Neil Alles
Journal:  Bone Rep       Date:  2019-10-21

9.  Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes.

Authors:  Jung-Yoon Choe; Ki-Yeun Park; Sung-Hoon Park; Sang-Il Lee; Seong-Kyu Kim
Journal:  Arthritis Res Ther       Date:  2013-02-13       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.